AstraZeneca PLC (NASDAQ:AZN) is one of the best performing pharma stocks in 2025. On January 7, Berenberg Bank reiterated a ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the ...

Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has been drawing attention after a period of solid share price gains. This is prompting investors to reassess how its current ...

April 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint alleging it misused its patents to ...

While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.

While AstraZeneca may be a major player in the oncology space, the company has been noticeably absent as the first wave of CAR-T therapies hit the market over the past five years. But movement is ...

For a pharma company selling respiratory drugs, climate change would probably mean more patients and increased sales. But AstraZeneca has committed to contributing its fair share to stop that trend.

President Donald Trump has not shied away from making demands of private industry, and he formalized one of them last week. On Thursday, he sent letters to 17 pharmaceutical companies, demanding that ...

Katarina Ageborg was appointed head of sustainability at AstraZeneca in 2015 and has served as chief compliance officer since 2011. AstraZeneca recently released its 7th annual sustainability report, ...

AstraZeneca PLC will announce its Q2 earnings next Thursday, 25th July. In Q1, the company showed 19% year-on-year revenue growth and 13% EPS growth. Guidance for 2024 is for double-digit growth at ...

The participant who triggered a global shutdown of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but ...